Tags

Type your tag names separated by a space and hit enter

An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India.
Vaccine. 2005 Jan 04; 23(7):897-900.V

Abstract

Purified Vero cell culture rabies vaccine "Abhayrab" manufactured by Human Biologicals Institute, Ooty, India was subjected for immunogenicity studies. Pre-exposure study was undertaken on 60 healthy volunteers (Group I) with vaccination on days 0, 7 and 21. A group of 75 patients of category II (Group II), 67 of category III (Group III) were given post-exposure prophylaxis and 88 patients of category III were administered with rabies immunoglobulins (Group IV) along with post-exposure prophylaxis as per World Health Organization (WHO) recommendations with a booster on day 90. The volunteers and patients vaccinated showed very few adverse side effects. The blood samples collected from volunteers (Group I) on days 14, 35 and 365 and patients (Group II-IV) on days 14, 30, 90 and 365 showed geometric mean titres (GMT) of >0.5 IU/ml. The study indicated new rabies vaccine manufactured in India was found to be safe and immunogenic.

Authors+Show Affiliations

Institute of Preventive Medicine, Narayanaguda, Hyderbad, India. gadeysampath@yahoo.co.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15603890

Citation

Sampath, G, et al. "An Immunogenicity Study of a Newly Introduced Purified Vero Cell Rabies Vaccine (Abhayrab) Manufactured in India." Vaccine, vol. 23, no. 7, 2005, pp. 897-900.
Sampath G, Reddy SV, Rao ML, et al. An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India. Vaccine. 2005;23(7):897-900.
Sampath, G., Reddy, S. V., Rao, M. L., Rao, Y. U., & Palaniappan, C. (2005). An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India. Vaccine, 23(7), 897-900.
Sampath G, et al. An Immunogenicity Study of a Newly Introduced Purified Vero Cell Rabies Vaccine (Abhayrab) Manufactured in India. Vaccine. 2005 Jan 4;23(7):897-900. PubMed PMID: 15603890.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India. AU - Sampath,G, AU - Reddy,Suhasini V, AU - Rao,M Lakshmi Prasad, AU - Rao,Y Udayabhaskara, AU - Palaniappan,C, PY - 2003/12/24/received PY - 2004/08/02/accepted PY - 2004/12/18/pubmed PY - 2005/3/16/medline PY - 2004/12/18/entrez SP - 897 EP - 900 JF - Vaccine JO - Vaccine VL - 23 IS - 7 N2 - Purified Vero cell culture rabies vaccine "Abhayrab" manufactured by Human Biologicals Institute, Ooty, India was subjected for immunogenicity studies. Pre-exposure study was undertaken on 60 healthy volunteers (Group I) with vaccination on days 0, 7 and 21. A group of 75 patients of category II (Group II), 67 of category III (Group III) were given post-exposure prophylaxis and 88 patients of category III were administered with rabies immunoglobulins (Group IV) along with post-exposure prophylaxis as per World Health Organization (WHO) recommendations with a booster on day 90. The volunteers and patients vaccinated showed very few adverse side effects. The blood samples collected from volunteers (Group I) on days 14, 35 and 365 and patients (Group II-IV) on days 14, 30, 90 and 365 showed geometric mean titres (GMT) of >0.5 IU/ml. The study indicated new rabies vaccine manufactured in India was found to be safe and immunogenic. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15603890/An_immunogenicity_study_of_a_newly_introduced_purified_Vero_cell_rabies_vaccine__Abhayrab__manufactured_in_India_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(04)00587-0 DB - PRIME DP - Unbound Medicine ER -